Twenty-four-hour proteinuria levels are associated with adverse pregnancy outcomes among women with CKD.

Abstract

Proteinuria is commonly measured to assess the renal status of chronic kidney disease (CKD) patients before the 20th week of gestation during pregnancy. High levels of proteiuria have been associated with adverse pregnancy outcomes. However, researchers have not clearly determined what baseline proteinuria levels would be associated with adverse pregnancy outcomes. This study aimed to analyse associations between proteinuria levels and adverse pregnancy outcomes among CKD patients treated with or without steroids/immunosuppressive therapy in early pregnancy. This retrospective study included the clinical information of 557 pregnant patients with CKD from 1 January 2009 to 31 December 2021. A multivariable logistic regression analysis was conducted to evaluate the risk of adverse pregnancy outcomes across various proteinuria ranges, which were further stratified by whether the patients were receiving steroids/immunosuppressive therapy. (i) Proteinuria was assessed on 24-h urine collection. The median (quartile) baseline proteinuria levels were 0.83g (0.20, 1.92) and 0.25g (0.06, 0.80) in the steroids/immunosuppressive therapy and therapy-free groups, respectively. (ii) CKD patients with adverse pregnancy outcomes had significantly higher proteinuria levels in the first trimester than patients without adverse pregnancy outcomes. (iii) The risk of adverse pregnancy outcomes increased with increasing baseline proteinuria levels (P<.001). (iv) In the early-pregnancy steroids/immunosuppressive therapy group, the risk of severe preeclampsia was higher in patients with higher baseline proteinuria levels (P<.007) [odds ratio (OR) 30.86 for proteinuria ≥5.00g/24h]; in the therapy-free group, the risks of severe preeclampsia, very-low-birth-weight infants, early preterm birth and foetal-neonatal death were higher in patients with higher baseline proteinuria levels (OR 53.16 for proteinuria ≥5.00g/24h; OR 37.83 for proteinuria ≥5.00g/24h; OR 15.30 for proteinuria ≥5.00g/24h; and OR 18.83 for proteinuria ≥5.00g/24h, respectively; P<.001, P<.001, P<.001 and P=.006, respectively). As shown in the present study, a baseline 24-h proteinuria level >1.00g was associated with adverse maternal outcomes. Furthermore, a 24-h proteinuria level >2.00g increased the incidence of adverse foetal events among CKD patients.